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BMC Cancer [1] was launched ten years ago at a time
when open access publishing was in its infancy.
Although initially looked upon with skepticism, the
open access publishing model, which provides an
unrestricted and free access to scientific and scholarly
work, has become increasingly accepted as a viable
model, with more than 7, 000 open access journals now
operating worldwide [2]. In a decade, this model has
moved from the fringe to the core of the publishing
industry.
BMC Cancer was one of the first journals to be open
access and exclusively published online. The journal
published 20 articles during its first year and has steadily
grown since then with over 490 articles already pub-
lished this year. BMC Cancer now boasts an impact fac-
tor of 3.15, which places it in the first quartile of the
“oncology” category. To celebrate this first very success-
f u ld e c a d ef o rt h ej o u r n a l ,w ep r e s e n tas p e c i a ls e r i e so f
commissioned articles that not only highlight the most
important advances in cancer research over the last ten
years, but also discuss the new developments we might
expect to see in the near future.
One major challenge in the treatment of cancer is to
diagnose the disease at an early stage in order to improve
prognosis. While several screening programmes exist for
common cancers such as colorectal and breast cancer,
they only detect cancers of one particular type [3,4]. In his
commentary, Ian Cree [5] discusses how technical
improvements in tests to detect circulating tumor mar-
kers, and indeed the potential for some molecules to act as
general tumor markers, raise the possibility of blood test-
based general screening for multiple cancers - in effect,
screening for who to screen. Recently, an increasing num-
ber of studies have suggested that micro-RNAs (miRs)
represent a promising new class of biomarkers for human
malignancies [6-8]. In their review, Fei-Fei Liu and col-
leagues [9] specifically focus on the potential role of
micro-RNAs as diagnostic and prognostic biomarkers in
human epithelial tumors.
The last decade has also seen huge developments in
sequencing technologies and several projects such as the
Cancer Genome Atlas [10] and the International Cancer
Genome Consortium [11] have aimed to provide a more
complete picture of the mutational profile of cancer via
large-scale analysis of cancer genomes. Hans Kristian
Moen Vollan and Carlos Caldas [12] discuss how
results of next generation sequencing hold the potential
to refine molecular classification of breast cancer by inte-
grating information from genomic signatures to existing
knowledge derived from histopathological sub-classifica-
tion. These advances could thus improve targeted cancer
therapy and prognosis.
It is becoming increasingly clear that a multi-drug
approach to targeted cancer therapy is needed due to
increasing drug resistance to individual therapeutic agents
[13,14]. In particular, Joanna Pancewicz and Christophe
Nicot [15] discuss how recent advances on the role of
Notch signaling pathway in the pathogenesis of human
leukemia suggest that multi-drug chemotherapy targeting
Notch signaling might be a promising therapeutic strategy
in various hematological disorders.
In his commentary, Dirk Vordermark [16] discusses
how the individualization of radiotherapy concepts and the
combination of radiotherapy with molecular approaches
are central to major developments in the field of radiation
oncology, and he outlines the particular role of BMC
Cancer as a platform for disseminating this research. Indi-
vidualized and targeted therapy approaches hold great pro-
mise in oncology but resistance to therapy remains to be
overcome. It is well-established that low tumor oxygena-
tion can cause poor response to radiation therapy [17,18].
Kevin Bennewith and Shoukat Dedhar discuss in their
review [19] how the clinical potential of hypoxic tumor
cells extends beyond the treatment of primary tumors, and
they elaborate on the promising role of hypoxic tumor
cells as targets for the treatment and prevention of meta-
static cancer.
This special issue sets the stage for ‘hot topics’ we
might expect to see in the coming decade, and BMC
Cancer is poised to be at the forefront of disseminating
this research in a rapid and freely-accessible manner. * Correspondence: Christna.Chap@biomedcentral.com
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